Genome-wide association and pathway analysis of left ventricular function after anthracycline exposure in adults

Pharmacogenetics and Genomics

Volumn 27, Issue 7, 2017, Pages 247-254

  Wells, Quinn S ^a,b   Veatch, Olivia J ^c   Fessel, Joshua P ^a   Joon, Aron Y ^e   Levinson, Rebecca T ^a,b   Mosley, Jonathan D ^a   Held, Elizabeth P ^a   Lindsay, Chase S ^a   Shaffer, Christian M ^a   Weeke, Peter E ^a,b,g   Glazer, Andrew M ^a   Bersell, Kevin R ^a   Van Driest, Sara L ^a,c   Karnes, Jason H ^a   Blair, Marcia A ^a   Lagrone, Lore W ^c   Su, Yan R ^a   Bowton, Erica A ^d   Feng, Ziding ^e   Ky, Bonnie ^f   Lenihan, Daniel J ^a   Fisch, Michael J ^c   Denny, Joshua C ^a,b   Roden, Dan M ^a   more..

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c Department of Neurology ^*  (United States)

^d Institute for Clinical and Translational Research   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Anthracycline; Cardiotoxicity; Genome wide association study; Pathway analysis

Indexed keywords

ANTHRACYCLINE; CYTOCHROME P450 2J2; DAUNORUBICIN; DNA; DOXORUBICIN; EPIRUBICIN; GLYCOSAMINOGLYCAN; IDARUBICIN;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL METABOLISM; COHORT ANALYSIS; DNA REPAIR; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE FREQUENCY; GENE LOCUS; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RADIONUCLIDE VENTRICULOGRAPHY; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSTHORACIC ECHOCARDIOGRAPHY; DEMOGRAPHY; DRUG EFFECTS; GENETICS; HEART STROKE VOLUME; MIDDLE AGED; REPRODUCIBILITY; SIGNAL TRANSDUCTION;

ADULT; ANTHRACYCLINES; COHORT STUDIES; DEMOGRAPHY; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 85019665792     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000284     Document Type: Article

References (50)

1. Shankar SM, Marina N, Hudson MM, Hodgson DC, Adams MJ, Landier W, et al. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics 2008;121:e387-e396.
2. Geisberg CA, Sawyer DB. Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. Curr Hypertens Rep 2010;12:404-410.
3. Forrest GL, Gonzalez B, Tseng W, Li X, Mann J. Human carbonyl reductase overexpression in the heart advances the development of doxorubicininduced cardiotoxicity in transgenic mice. Cancer Res 2000;60:5158-5164.
4. Dell'Acqua G, Polishchuck R, Fallon JT, Gordon JW. Cardiac resistance to adriamycin in transgenic mice expressing a rat alpha-cardiac myosin heavy chain/human multiple drug resistance 1 fusion gene. Hum Gene Ther 1999;10:1269-1279.
5. Zhang S, Liu X, Bawa-Khalfe T, Lu L-S, Lyu YL, Liu LF, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012;18:1639-1642.
6. Khiati S, Dalla Rosa I, Sourbier C, Ma X, Rao VA, Neckers LM, et al. Mitochondrial topoisomerase I (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity. Clin Cancer Res 2014;20:4873-4881.
7. Abdel-aleem S, el-Merzabani MM, Sayed-Ahmed M, Taylor DA, Lowe JE. Acute and chronic effects of adriamycin on fatty acid oxidation in isolated cardiac myocytes. J Mol Cell Cardiol 1997;29:789-797.
8. Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, Rosenberger A, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005;112:3754-3762.
9. Rajic V, Aplenc R, Debeljak M, Prestor VV, Karas-Kuzelicki N, Mlinaric- Rascan I, et al. Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. Leuk Lymphoma 2009;50:1693-1698.
10. Blanco JG, Sun C-L, Landier W, Chen L, Esparza-Duran D, Leisenring W, et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes: a report from the Children's Oncology Group. J Clin Oncol 2012;30:1415-1421.
11. Visscher H, Ross CJD, Rassekh SR, Barhdadi A, Dubé M-P, Al-Saloos H, et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 2012;30:1422-1428.
12. Lubieniecka JM, Graham J, Heffner D, Mottus R, Reid R, Hogge D, et al. A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor. Front Genet 2013;4:231.
13. Aminkeng F, Bhavsar AP, Visscher H, Rassekh SR, Li Y, Lee JW, et al. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nat Genet 2015;47:1079-1084.
14. Vasan RS, Glazer NL, Felix JF, Lieb W, Wild PS, Felix SB, et al. Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data. JAMA 2009;302:168-178.
15. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015;131:1981-1988.
16. Roden DM, Pulley JM, Basford MA, Bernard GR, Clayton EW, Balser JR, et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther 2008;84:362-369.
17. Bowton E, Field JR, Wang S, Schildcrout JS, Van Driest SL, Delaney JT, et al. Biobanks and electronic medical records: enabling cost-effective research. Sci Transl Med 2014;6:234cm3.
18. Altman AJ. Supportive care of children with cancer. Baltimore: JHU Press; 2004.
19. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 2009;5:e1000529.
20. Yaspan BL, Bush WS, Torstenson ES, Ma D, Pericak-Vance MA, Ritchie MD, et al. Genetic analysis of biological pathway data through genomic randomization. Hum Genet 2011;129:563-571.
21. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000;28:27-30.
22. Kim K-C, Geng L, Huang S. Inactivation of a histone methyltransferase by mutations in human cancers. Cancer Res 2003;63:7619-7623.
23. Khurana S, Kruhlak MJ, Kim J, Tran AD, Liu J, Nyswaner K, et al. A macrohistone variant links dynamic chromatin compaction to BRCA1-dependent genome maintenance. Cell Rep 2014;8:1049-1062.
24. Shukla PC, Singh KK, Quan A, Al-Omran M, Teoh H, Lovren F, et al. BRCA1 is an essential regulator of heart function and survival following myocardial infarction. Nat Commun 2011;2:593.
25. Muraosa Y, Takahashi K, Yoshizawa M, Shibahara S. cDNA cloning of a novel protein containing two zinc-finger domains that may function as a transcription factor for the human heme-oxygenase-1 gene. Eur J Biochem 1996;235:471-479.
26. Choi AM, Alam J. Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury. Am J Respir Cell Mol Biol 1996;15:9-19.
27. Otterbein LE, Mantell LL, Choi AM. Carbon monoxide provides protection against hyperoxic lung injury. Am J Physiol 1999;276:L688-L694.
28. Otterbein LE, Hedblom A, Harris C, Csizmadia E, Gallo D, Wegiel B. Heme oxygenase-1 and carbon monoxide modulate DNA repair through ataxiatelangiectasia mutated (ATM) protein. Proc Natl Acad Sci 2011;108:14491-14496.
29. Gu J, Song Z-P, Gui D-M, Hu W, Chen Y-G, Zhang D-D. Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in lymphoma nude mice by heme oxygenase-1 induction. Cardiovasc Toxicol 2012;12:341-349.
30. Archer SL, Gragasin FS, Wu X, Wang S, McMurtry S, Kim DH, et al. Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11, 12-epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BK(Ca) channels. Circulation 2003;107:769-776.
31. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999;285:1276-1279.
32. Fleming I. Epoxyeicosatrienoic acids, cell signaling and angiogenesis. Prostaglandins Other Lipid Mediat 2007;82:60-67.
33. Zhang Y, El-Sikhry H, Chaudhary KR, Batchu SN, Shayeganpour A, Jukar TO, et al. Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol 2009;297:H37-H46.
34. Beer M, Seyfarth T, Sandstede J, Landschütz W, Lipke C, Köstler H, et al. Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)P-SLOOP magnetic resonance spectroscopy. J Am Coll Cardiol 2002;40:1267-1274.
35. Doenst T, Pytel G, Schrepper A, Amorim P, Färber G, Shingu Y, et al. Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload. Cardiovasc Res 2010;86:461-470.
36. Liddy KA, White MY, Cordwell SJ. Functional decorations: post-translational modifications and heart disease delineated by targeted proteomics. Genome Med 2013;5:20.
37. Parker BL, Palmisano G, Edwards AVG, White MY, Engholm-Keller K, Lee A, et al. Quantitative N-linked glycoproteomics of myocardial ischemia and reperfusion injury reveals early remodeling in the extracellular environment. Mol Cell Proteomics 2011;10:M110.006833.
38. Koitabashi N, Kass DA. Reverse remodeling in heart failure: mechanisms and therapeutic opportunities. Nat Rev Cardiol 2012;9:147-157.
39. Chakravarti R, Adams JC. Comparative genomics of the syndecans defines an ancestral genomic context associated with matrilins in vertebrates. BMC Genomics 2006;7:83.
40. Finsen AV, Woldbaek PR, Li J, Wu J, Lyberg T, Tønnessen T, et al. Increased syndecan expression following myocardial infarction indicates a role in cardiac remodeling. Physiol Genomics 2004;16:301-308.
41. van Almen GC, Swinnen M, Carai P, Verhesen W, Cleutjens JPM, D'hooge J, et al. Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy. J Mol Cell Cardiol 2011;51:318-328.
42. Hu Y-Y, Zheng M-H, Zhang R, Liang Y-M, Han H. Notch signaling pathway and cancer metastasis. Adv Exp Med Biol 2012;727:186-198.
43. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008;8:387-398.
44. Croquelois A, Domenighetti AA, Nemir M, Lepore M, Rosenblatt-Velin N, Radtke F, et al. Control of the adaptive response of the heart to stress via the Notch1 receptor pathway. J Exp Med 2008;205:3173-3185.
45. You J, Wu J, Jiang G, Guo J, Wang S, Li L, et al. Olmesartan attenuates cardiac remodeling through DLL4/Notch1 pathway activation in pressure overload mice. J Cardiovasc Pharmacol 2013;61:142-151.
46. Li Y, Hiroi Y, Liao JK. Notch signaling as an important mediator of cardiac repair and regeneration after myocardial infarction. Trends Cardiovasc Med 2010;20:228-231.
47. Malekar P, Hagenmueller M, Anyanwu A, Buss S, Streit MR, Weiss CS, et al. Wnt signaling is critical for maladaptive cardiac hypertrophy and accelerates myocardial remodeling. Hypertension 2010;55:939-945.
48. Bergmann MW. WNT signaling in adult cardiac hypertrophy and remodeling: lessons learned from cardiac development. Circ Res 2010;107:1198-1208.
49. Deng S, Wojnowski L. Genotyping the risk of anthracycline-induced cardiotoxicity. Cardiovasc Toxicol 2007;7:129-134.
50. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet 2001;29:306-309.